Trial Profile
Evaluation of imatinib (GLIVEC) after induction therapy in patients aged more than 55 years with Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL): a non randomised, controlled, open, multicentric, international phase II clinical study (CSTI 571 AFR09 trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Antineoplastics; Corticosteroids; Cyclophosphamide; Daunorubicin; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 07 Nov 2005 New trial record.